Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma

Inclusion Criteria: * Histologically proven resectable adenocarcinoma of the lower oesophagus and gastric-oesophageal junction * Tumour stage: T2-3 N0-1 M0, as assessed by endoscopic ultrasound and CT-scan of thorax and abdomen and ultrasound neck region. For the patients treated in this study the gastro-oesophageal junctional tumors will be staged as oesophageal tumors with respect to their lymphnode metastases. * Age \>18y and written informed consent after at least 4 days of deliberation time from the moment the patient information has been given and has been explained. * Weight loss \< 10% in 0.5 yr * WHO performance status 0-1 * No prior radiotherapy or chemotherapy for the adenocarcinoma of the oesophagus Exclusion Criteria: * Previous malignancy other than basal cell carcinoma of the skin or local resection for cervical carcinoma in situ. * Inadequate organ function as defined by: * Inadequate haematology (Hb \< 5,5 mmol/L (red blood cell transfusions are allowed to increase the Hb at the discretion of the investigator) - neutrophils \< 1,5 109/L -platelets \<100\*109/L), * Liver enzyme elevation (bili \> 1,5\*ULN - ASAT \> 2,5\*ULN - ALAT \> 2,5\*ULN) or * Impaired renal function (creatinine clearance by cockcroft \< 60 cc/min) * Proteinuria \>1,0gr/24hr * Tumour stage: M1a and/or tumour length \> 8 cm and/or \> 5 cm radially * Major surgery within 4 weeks prior to the start of study treatment * Bleeding disorder * Known allergy to one of the study drugs used * Use of any substance known to interfere with the chemotherapy clearance * Previous radiotherapy to the chest * Significant concomitant diseases preventing the safe administration of study drugs or likely to interfere with study assessments * Uncontrolled angina pectoris; cardiac failure or clinically significant arrhythmias * Continuous use of immunosuppressive agents * Concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine * Prior exposure to anti-EGFR targeting agents. * Hearing loss \> 25 dB under normal * Neurotoxicity \> CTC grade 1 * Pregnancy or breast feeding * Patients (M/F) with reproductive potential not implementing adequate contraceptive measures